Editorial: A rational approach to the use of atypical antipsychotics

Israel Journal of Psychiatry and Related Sciences

Volumn 40, Issue 2, 2003, Pages 79-81

  Belmaker, R H ^a   Bersudsky, Yuly ^a  

^a MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RACLOPRIDE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

AGRANULOCYTOSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG DESIGN; DRUG MECHANISM; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL PRACTICE; PHARMACEUTICAL CARE; PRESCRIPTION; SIDE EFFECT; WEIGHT GAIN; ATTITUDE; CLASSIFICATION; PSYCHOSIS;

ANTIPSYCHOTIC AGENTS; ATTITUDE; HUMANS; PSYCHOTIC DISORDERS;

EID: 2442505435     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Editorial

References (4)

1. Kapur S, Seeman P. Does fast dissociation from the dopamine D-2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158:360-369.
2. Hertel P, Fagerquist MV, Svensson TH. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha-2 adrenoceptor blockage. Science 1999;286:105-107.
3. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376.
4. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783.